These guidelines have been developed by an expert panel of haemophilia treaters to support the appropriate management of people with haemophilia in Egypt. Although the guidelines are based primarily on the World Federation of Hemophilia (WFH) Guidelines for the Management of Hemophilia, they aim to address unmet needs and local requirements in the Egyptian setting.
1. World Health Organization. Country Cooperation Strategy for WHO and Egypt 2010-2014. Cairo, Egypt: World Health Organization Regional Office for the Eastern Mediterranean, 2010. Available from http://who.int/countryfocus/cooperation_strategy/ccs_egy_en.pdf?ua=1 (accessed October 2016).
2. World Federation of Hemophilia. Guidelines for the management of hemophilia. 2nd edition. 2012. Available from https://www1.wfh.org/publications/files/pdf-1472.pdf (accessed 24 September 2018).
3. Kabil N, ElAlfy MS, Metwalli N. Evaluation of the oral health situation of a group of Egyptian haemophilic children and their re-evaluation following an oral hygiene and diet education programme. Haemophilia 2007;13:287-92.
4. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of the World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-e47.
5. Lobet S, Hermans C, Lambert C. Optimal management of hemophilic arthropathy and hematomas. J Blood Med 2014: 5; 207-18.
6. El-Zanaty F, Way A. Egypt Demographic and Health Survey 2008. Cairo, Egypt: Ministry of Health, El-Zanaty and Associates, and Macro International, 2009. Available from https://dhsprogram.com/pubs/pdf/fr220/fr220.pdf (accessed 24 September 2018).
7. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis 2013; 13: 288.
8. El Ekiaby M, Moftah F, Goubran H, et al. Viremia levels in hepatitis C infection among Egyptian blood donors and implications for transmission risk with different screening scenarios. Transfusion 2015; 55: 1186-94.
9. Cassis FR, Querol F, Forsyth A, Iorio A, HERO International Advisory Board. Psychosocial aspects of haemophilia: a systematic review of methodologies and findings. Haemophilia 2012; 18: e101-14.
10. Tantawy A, von Mackenssen S, Mohammed AM, et al. Health‑related quality of life in Egyptian children and adolescents with hemophilia A. Pediatr Hematol Oncol 2011; 28: 222-9.
11. Bottos AM, Zanon E, Sartori MT, Girolami A. Psychological aspects and coping styles of parents with haemophilic child undergoing a programme of counselling and psychological support. Haemophilia 2007; 13: 305-10.
12. Zulfikar B, Karaman MI, Ovali F. Circumcision in hemophilia: an overview. 2003. Available from www1.wfh.org/publication/files/pdf-1170.pdf (accessed October 2016).
13. Elalfy MS, Elbarbary NS, Eldebeiky MS, El Danasoury AS. Risk of bleeding and inhibitor development after circumcision of previously untreated or minimally treated severe hemophilia A children. Pediatr Hematol Oncol 2012; 29: 485-93.
14. Paisley S, Wight J, Currie E, Knight C. The management of inhibitors in haemophilia A: introduction and systematic review of current practice. Haemophilia 2003; 9: 405-17.
15. Rivard GE, Rothschild C, Toll T, Achilles K. Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective noninterventional study. Haemophilia 2013; 19: 449-55.
16. European Medicines Agency. Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. EMA/CHMP/BPWP/144533/2009. Available from https://www.ema.europa.eu/documents/scientific-guideline/guideline-clinical-investigationrecombinant-human-plasma-derived-factor-viii-productsfirst-version_en.pdf (accessed 4 October 2018)..
17. Iorio A, Puccetti P, Makris M. Clotting factor concentrate switching and inhibitor development in hemophilia A. Blood 2012; 120: 720-27.
18. Marcucci M, Mancuso ME, Santagostino E, et al. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis. Thromb Haemost 2015; 113: 958-67.
19. Di Minno G, Canaro M, Ironside JW, et al. Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. Haematologica 2013; 98: 1495-98.
20. Di Minno G, Canaro M, Ironside JW, et al. Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats. Semin Thromb Haemost 2013; 39: 779-93.
21. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet 2007; 370: 439-48.
22. Abdel-Messih IY, Habashy DM, Moftah SG, ElAlfy MS. Persistent factor VIII inhibitors and orthopaedic complications in children with severe haemophilia A. Haemophilia 2011; 17: 490-3.
23. Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016; 374: 2054-64.
24. Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus 2012; 10: 165-8.
25. Fischer K, van der Bom JG, Molho P, et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-52.
26. Elekiaby A, El Saied H, Elekiaby M. Five years of tailored low dose prophylaxis in a small cohort of kids with severe hemophilia A using SD-F cryoprecipitate. Poster no. PO169 presented at the World Federation of Hemophilia Congress; 24-28 July 2016; Orlando, FL.
27. El-Kiaby M, Goubran HA, Radosevich M, et al. Pharmacokinetic study of minipooled solvent/detergent filtered cryoprecipitate factor VIII. Haemophilia 2011; 17: e884-8.
28. BeneFIX: Summary of product characteristics, 2016.
30. Rodriguez-Merchan EC, Caviglia HA, Magallon M, Perez- Bianco R. Chemical synovectomy vs. radioactive synovectomy for the treatment of chronic haemophilic synovitis: a prospective short- term study. Haemophilia 1997; 3: 118-22.